Sign in / Join Now
ETFs & Funds
50:50 chance of FDA approval without P3. Huge unmet medical need vs. extremely small P2 study.
Upside ridiculous if you are right. 10-15 more patients would have helped.
Add a reply...
Latest StockTalks »
people get SRPT breaking news and analysis by email alert.
Get email alerts on SRPT »
Sarepta Therapeutics, Inc.
Get latest price
From other sites
Sarepta's DMD Drug Should Have A Strong Launch, But Long-Term Prospects Uncertain
at Benzinga (Thu, 7:44AM)
Sarepta Therapeutics To Announce Third Quarter 2016 Financial Results And Recent Corporate Developments On October 27, 2016
at TheStreet (Mon, 8:30AM)
For Sarepta, Exondys 51 Might Be Just The Beginning: Credit Suisse Starts At Outperform
at Benzinga (Oct 18, 2016)
Exclusive: SunTrust Managing Director Goes Over Sarepta Therapeutics' Story
at Benzinga (Oct 17, 2016)
Short Interest In Sarepta Therapeutics Moves 21% Lower
at Nasdaq.com (Oct 13, 2016)